IMMUNIC, INC.
IMUX$83M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK
Drugs in Pipeline
3
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
IMUX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
IMU-838 tablets
Multiple Sclerosis, Relapsing-Remitting
IMU-838
Multiple Sclerosis
IMU-838 (30 mg/day)
Relapsing-Remitting Multiple Sclerosis (RRMS)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMU-838 tablets | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
IMU-838 | Phase 3 | Multiple Sclerosis | - | - |
IMU-838 (30 mg/day) | Phase 2 | Relapsing-Remitting Multiple Sclerosis (RRMS) | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply